ACPA: anti-citrullinated protein antibody; csDMARDs: conventional synthetic disease-modifying antirheumatic drugs; lda: low disease activity; rem: remission; RF: rheumatoid factor. *Obesity: body mass index ≥ 27.5 kg/m2.
Declarations
Acknowledgments
We would like to thank the Director General of Health Malaysia for his permission to publish this article.
Author contributions
PSO: Conceptualization, Methodology, Software, Formal analysis, Investigation, Data curation, Writing—original draft, Writing—review & editing, Visualization. MC: Data curation, Investigation, Validation. AKB: Data curation, Investigation, Validation. All authors read and approved the submitted version.
Conflicts of interest
The authors declare that there are no conflicts of interest.
Ethical approval
This study was approved by the Medical Research and Ethics Committee, Ministry of Health Malaysia (NMRR ID: 25-03639-UE5). This study was conducted in accordance with the ethical principles of the World Medical Association Declaration of Helsinki.
Consent to participate
Individual informed consent was waived by the Malaysian Medical Research and Ethics Committee due to the retrospective nature of the study and the use of existing medical records.
Consent to publication
Not applicable.
Availability of data and materials
The data that support the findings of this study are available from the corresponding author upon reasonable request
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Markusse IM, Akdemir G, Dirven L, Goekoop-Ruiterman YP, van Groenendael JH, Han KH, et al. Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment.Ann Intern Med. 2016;164:523–31. [DOI] [PubMed]
Smolen JS, Edwards CJ, Konzett V, Laskou F, Aletaha D, Caporali R, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update.Ann Rheum Dis. 2026;85:991–1009. [DOI] [PubMed]
Cohen SB, Alten R, Kameda H, Hala T, Radominski SC, Rehman MI, et al. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.Arthritis Res Ther. 2018;20:155. [DOI] [PubMed] [PMC]
Traynor K. FDA approves tofacitinib for rheumatoid arthritis.Am J Health Syst Pharm. 2012;69:2120. [DOI] [PubMed]
Xu Z, Wang Y, Liu Z, Zhang R, Zhou Y, Yu J, et al. A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjects.Int Immunopharmacol. 2022;109:108780. [DOI] [PubMed]
Phatak S, Khenat A, Malandkar M, Amin S. Real-world evidence of the effectiveness and safety of generic tofacitinib in rheumatoid arthritis patients: a retrospective, single-centre analysis from Western India.Clin Rheumatol. 2022;41:2961–6. [DOI] [PubMed] [PMC]
Nguyen E, Weeda ER, Sobieraj DM, Bookhart BK, Piech CT, Coleman CI. Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review.Curr Med Res Opin. 2016;32:1281–90. [DOI] [PubMed]
Pearson SD, Towse A, Lowe M, Segel CS, Henshall C. Cornerstones of ‘fair’ drug coverage: appropriate cost sharing and utilization management policies for pharmaceuticals.J Comp Eff Res. 2021;10:537–47. [DOI] [PubMed]
Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force.Ann Rheum Dis. 2010;69:631–7. [DOI] [PubMed] [PMC]
Kim YE, Ahn SM, Oh JS, Kim YG, Lee CK, Yoo B, et al. Clinical Characteristics and Management for Flares in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs.Int J Rheum Dis. 2026;29:e70631. [DOI] [PubMed]
Zhao J, Huang H, Wang Y, Deng X, Geng Y, Zhang X, et al. Real-World Clinical Equivalence of Generic and Branded Tofacitinib: A Prospective Longitudinal Cohort Study in Patients With Rheumatoid Arthritis.Mayo Clin Proc. 2024;99:26–38. [DOI] [PubMed]
Camacho LH, Frost CP, Abella E, Morrow PK, Whittaker S. Biosimilars 101: considerations for U.S. oncologists in clinical practice.Cancer Med. 2014;3:889–99. [DOI] [PubMed] [PMC]
Wang Y, Wen S, Zhao Y, Gui L, Mou Y, Wang D. New polymorph of tofacitinib citrate and in vitro equivalence study of its sustained-release tablets.PLOS One. 2025;20:e0332664. [DOI] [PubMed] [PMC]
Fleischmann R, Kremer J, Tanaka Y, Gruben D, Kanik K, Koncz T, et al. Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies.Int J Rheum Dis. 2016;19:1216–25. [DOI] [PubMed] [PMC]
Lee EB, Yamanaka H, Liu Y, Tsai WC, Chen C, Kwok K, et al. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.Int J Rheum Dis. 2019;22:1094–106. [DOI] [PubMed] [PMC]
Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al.; ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.N Engl J Med. 2012;367:495–507. [DOI] [PubMed]
van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis.N Engl J Med. 2012;367:508–19. [DOI] [PubMed]
Hassali MA, Alrasheedy AA, McLachlan A, Nguyen TA, Al-Tamimi SK, Ibrahim MI, et al. The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use.Saudi Pharm J. 2014;22:491–503. [DOI] [PubMed] [PMC]
